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807-1  Intraoperative Cell-Cycle Blockade Therapy Using E2F 
Decoy for Prevention of Early Atherosclerosis in 
Coronary Bypass Vein Grafts: A Volumetric IVUS 
Subanalysis From a Prospective Randomized Double 
Blind Clinical Trial 
Mitsuvasu Terashima, Eberhard Grube, Takefumi Takahashi, Hideaki Kaneda, Thomas 
Felderhoff, Stein Iversen, Paul G. Yock, Yasuhiro Honda, Peter J. Fitzgerald, Stanford 
University, Stanford, California, Heart Center Siegburg, Siegburg, Germany. 
Baokground: Previous experimental and peripheral studies of vein grafts have shown 
that ex vivo cell-cycle blockade therapy using E2F Decoy inhibits neointimal hyperplasia 
and subsequent accelerated atherosclerosis -- the primary factors in late graft failure. 
The aim of this study was to investigate the safety and efficacy of intraoperative cell- 
cycle blockade therapy on human coronary saphenous vein bypass grafts (SVG) using 
volumetric intravascular ultrasound (IVUS). 
Methods: Decoy oligodeoxynucleotide, which binds and inactivates the pivotal cell-cycle 
transcription factor E2F, was delivered to the tissue ex vivo using a transfection device 
under completely non-distending conditions. Patients were assigned to either the treat- 
ment group (40 pM E2F decoy) or the placebo group (normal saline alone) in a prospec- 
tive, randomized, and double-blind manner. IVUS was performed on a subset of grafts 
with automated pullback at 12 months following surgery. On the cross-sectional IVUS 
image, intimal area was measured as the area of an internal hypoechoic layer between 
the lumen/intimal border and the external border of hypoechoic layer (EHL). Volumetric 
IVUS analysis was performed over a 50-ram SVG segment (10 mm to 60 mm from the tip 
of guiding catheter or SVG odfice) using Simpson's method, 
Results: Volumetric analysis was available in 65 grafts (35 E2F-decoy-treated : 30 pla- 
cebo) at 12 months. Intimal volume/5Omm and standardized intimal volume index [intimal 
volume / EHL volume, %) of the E2F group were significantly less than those of the pla- 
cebo group (intimal volume/50mm: 78.6_+45.6 mm 3 vs 114.8_+78.3 mm 3, p=0.024, and 
standardized intimal volume index: 12.5_+6.0% vs 18.4_+10.1%, p=0.005). There was no 
difference in EHL-volume/50mm between the two groups. No adverse IVUS findings 
were observed in either the E2F or the placebo groups. 
Conclusion: Volumetric IVUS analysis demonstrated that intraoperative cell-cycle block- 
ade therapy with E2F Decoy significantly suppressed early neointimal hyperplasia of 
human coronary saphenous vein grafts. This new approach may contribute to reducing 
long-term morbidity and mortality following primary coronary bypass with saphenous vein 
grafts. 
9:30 a.m. 
807-2 A Tissue Engineered Stent for Cell-Based Vascular 
Gene Transfer 
Carmelo J. Panetta. Katsumi Miyauchi, David Berry, Robert D. Simari, David R. Holmes, 
Robert S. Schwartz, Noel M. Caplice, Mayo Foundation and Clinic, Rochester, 
Minnesota, Juntendo Universi~ Tokyo, Japan. 
Background: Cell based gene transfer using a stent platform would provide significant 
advantages in terms of site-specific gene expression in the vasculature. The current 
study presents a novel stent design that allows stable in vivo transgene expression over 
a 4 week period in the vasculature. 
Methods: A fiber matrix mesh was attached to Wiktor stent end coated with fibronectin 
prior to seeding with autologous porcine smooth muscle cells (SMC), which were stably 
transduced with a plasmid encoding green fluorescence protein (GFP). Cells were grown 
to confluence in the mesh-stent prior to deployment in the porcine coronary artery. Four 
animals were studied, each receiving one autologous seeded mesh-stent. After four 
weeks, quantitative coronary angiography (QCA) was performed on each animal prior to 
sacrifice. The coronary containing the mesh-stent was removed, a section was plastic 
embedded for hemotoxylin and eosin stain and the other section for fluorescent micros- 
copy. The cells were removed from the vessel, and the number of GFP expressing cells 
were counted using flow cytometry. 
Results: Fibronectin coating of the mesh allowed 20 fold greater seeding of cells com- 
pared no coating (4.9 x 105 +/- 0.4 x 105 vs. 0.2 x 105 +/- 0.03 x 10 s cells/cm 2 mesh; 
<0.001, n=6). Stable in vivo GFP expression within the mesh stent was demonstrated 
four weeks after implantation in the porcine coronary artery by fluorescent microscopy 
and flow cytometry. No significant change in GFP positive cell number within the stent 
occurred in vivo when compared to pre-insertion analysis of a companion cell seeded 
mesh-stent (5.8 x 106 +/- 1.5 x 108 vs. 5.3 x 106 +/- 0.7 x 106 cells/cm 2 mesh; p=O.3). 
QCA revealed a maximal mean percent stenosis of 13.5 +/- 5.9 % (n=4) and histologic 
analysis revealed no apparent inflammatory infiltrate in the stented segment. 
Conclusions: This is the first in vivo study to show stable cell-based gene transfer of 
large numbers of genetically engineered cells using a stent platform, These results have 
implications for gene therapy where long term delivery of transgene is a desirable thera- 
peutic option. 
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9:45 a.m. 
A New Approach for Inhibition of Neointimal Lesion 
' Formation by Targeting Endothelln Expression Through 
CAAT/Enhancer Binding Protein Decoy OIIgonucleotlde 
Ute Kelkenberg, Andreas H. Wagner, Jasmin Sarhaddar, Markus Hecker, Heiko E. van 
der Leven,/-lannover Medical School Hannover, Germany, University of GSttingen, 
G~ttingen, Germany. 
Background: Deformation-induced synthesis of endothelin-1 (ET-1) may play a pivotal 
role in restenosis following percutaneous transluminal angioplasty. Thus, inhibition of ET- 
1-synthesis may be a potential promising therapeutic approach to treat restenosis. Since 
effective inhibitors of preproendothelin 1 processing to ET-1 are not available, we 
employed decoy oligonucleotides (dODN) to evaluate the effect of genetically engi- 
neered inhibition of ET-1 expression in vivo. 
Methods: We analysed carotid arteries of hypercholesterolemic rabbits after balloon 
injury and incubation with therapeutic decoy (CAAT/enhancer binding protein [C/EBP] 
consensus dODN [10 ~M, 30 min] or control decoys (C/EBP mutant dODN or buffer; n=7/ 
group). Efficiency of decoy uptake was demonstrated using Texas-red labelled decoys. 
Results: 2 days after transduction, C/EBP consensus decoy application resulted in sig- 
nificant reduction of C/EBP activity (electrophoretic mobility shift assay) and ET-1 expres- 
sion (immunohistochemistry). 28 days post balloon injury we saw a significant reduction 
of intimal thickening (computerized morphometry; intima/media-ratio: 1.13 + 0.22 [C/EBP 
consensus dODN] vs. 1.75 _+ 0.45 [controls]; mean ± SEM, n = 7, p = 0.003). Macroph- 
ages were found throughout the intima of untreated and mutant decoy-dODN-transfected 
arteries corresponding to areas of macroscopic plaque. In the C/EBP consensus decoy- 
treated animals, only isolated macrophages in areas o1 small neointimal accumulation 
and no foam cells were observed (macrophage-positive area: 10.4 % _+ 4.6 [C/EBP con- 
sensus dODN] vs. 17.2 % + 4.9 [controls]; n = 7, p = 0.04). 
Conclusion: These data indicate that intravascular application of a therapeutic decoy 
inhibiting C/EBP activity may be a feasible, safe, and effective method to reduce resteno- 
sis following balloon injury, especially under hypercholesterolemic onditions. 
10:00 a,m. 
807-4 Applicability of a Highly Eff ic ient  E lectro-Gene Transfer 
Approach for the Human Heart 
Luvi Sen, Guanggen Cui, Jack Judy, Hillel Laks, UCLA Medical Center/UCLA School of 
Medicine, Los Angeles, California. 
Electroporation is a technique involving the application of short duration, high intensity 
electric field pulses to cells. It is commonly used for in vitro gene transfeotion of cell lines 
and primary cultures, but limited work has been reported in small animal organs and tis- 
sue. Recently, we have established a novel electroporation system for ex viva gene 
transfer in large animal and human hearts. This device consisted of two electrode arrays 
directly in contact with the endocardium and epicardium in order to achieve uniform elec- 
troporation-enhanced gene transfer to the entire human heart. Using our recently devel- 
oped rabbit heteretopic functional heart transplant model, we compared the efficiency of 
ex viva intracoronary recombinant human intedeukine 10 (IL-10) gene transfer, mediated 
by either electroporation (EP), liposome (LP) or adenovirus (AD). In EP group, the burst 
of electric pulses (pulse length 5 ms, number of pulse 10, burst-interval 2 min) was 
applied to the heart during and after ex viva intracoronary gene infusion for 20 minutes. 
With 10mV/om electric field strength, transgene was homogeneously transferred into the 
whole rabbit heart in 3-10 minutes. A significant increase in IL-10 mRNA level was 
observed 2 hours and reached a peak 3 days after gene transfer. In EP group, the trans- 
gone expression in the donor left ventricular myocardium was more than 5 times higher 
compared with that in the LP group, and 1.25 fold higher than that in AD group (n=8, 
p<0.01). The increase in transgene expression was paralleled with IL-10 protein expres- 
sion. The distribution of the electroporation-mediated transgene expression was much 
more uniform than that in liposome-mediated gene transfer and adenovirus-mediated 
gene transfer. The hemodynamic and electrophysiotogic parameters recorded from the 
donor heart were the same in EP group and the control group 6 days after transplanta- 
tion. The arrhythmogenic effect was highest in AD group, less in LP group, and none in 
EP group. These results suggest that this new electroporation-mediated gene transfer is 
highly efficient and no significant cardiac adverse effect and is potentially applicable for 
ex viva or in viva gene delivery in human heart. 
10:15 a.m. 
807-5 U l t rasound in Con junct ion  With an Ultrasonic-Reflective 
Transfection Agent Enhances Gone Delivery to Cel ls  
Shaolina Huana, David D. McPherson, Robed C. MacDonald, Northwestern University, 
Chicago and Evanston, Illinois. 
Cationic liposomes have been developed that both provide ultrasonic enhancement and 
gene delivery to a target site. Low level ultrasound may enhance transfection, while 
retaining acoustic properties. 
Methods: Liposomes consisting of cationic phospholipid (O-ethyldimyristoylphosphati- 
dylcholine; EDMPC) and cholesterol were prepared according to a procedure previously 
described for anionic lipids and involving dispersion of the lipids in mannitol solution, lyo- 
philization and rehydration. The liposomes were combined with DNA to form lipoplexes, 
which only slightry diminished ultrasound reflectivity. Cultured cells in 6-well plates were 
exposed to 1-Mhz ultrasound (0.5 W/cm 2, 30 sac) in the presence of the acoustic 
lipoplexes. Quantification of transfection efficiency was by -galactosidase expression and 
that of DNA uptake by fluorescence of YOYO-rabeled -galactosidase plasmid (-gal DNA). 
Results: Uptake of DNA into vascular smooth muscle cells and transfection of BHK cells 
